1-20 of 859 results for subject:Tumours
Librarians' tools
- Search time
- 0.347 seconds
- Solr query time
- 0.005 seconds
- Search query
- subject:Tumours
- We searched for
- subject_t:Tumours OR subject_ses:93354
Type
House
Session
Year
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, what steps she is taking to increase Government funding for research to improve outcomes for brain tumour patients.
To ask the Secretary of State for Health and Social Care, what steps she is taking to increase Government funding for research to improve outcomes for brain tumour patients.
I refer the Hon Member to the answer provided to the Rt Hon The Lord Hunt of Kings Heath OBE on 16 July 2026 in response to Question HL1674.
Available data on this issue is also published by the National Institute for Health and Care Research, at the following link:
To ask His Majesty's Government what estimate have they made, if any, of the total audited, reconciled and direct public expenditure on brain tumour research since 2018; and what proportion of this amount derives from direct expenditure, attributed infrastructure expenditure, estimation, reconciliation adjustments or overlap with any other reported figure.
To ask His Majesty's Government what estimate have they made, if any, of the total audited, reconciled and direct public expenditure on brain tumour research since 2018; and what proportion of this amount derives from direct expenditure, attributed infrastructure expenditure, estimation, reconciliation adjustments or overlap with any other reported figure.
I refer the Noble Lord Hunt to the answers provided on 15 July in response to Question HL1677 and 16 July in response to Question HL1674.
Further to the answer provided on 15 July in response to Question HL1677, over eight years, from 2018/19 to 2025/26, UK Research and Innovation (UKRI) committed £66.3 million to brain tumour research. UKRI also supported 93 studentships over this period. All associated work packages for the National Institute for Health and Care Research Brain Tumour Research Consortium have now been fully executed.
The information requested is not held by the Medicines and Healthcare products Regulatory Agency.
Information on trials supported through the Cancer Vaccine Launch Pad (CVLP) can be found on their website. The platform is designed to be company and clinical trial agnostic so any company can contact the CVLP to explore how the platform can support their research.
Other information is not available as it is not held in the format requested or is not held centrally.
To ask the Secretary of State for Health and Social Care, what consideration she has given to the potential impact of the use of Depo-Provera on trends in the level of meningioma.
To ask the Secretary of State for Health and Social Care, what consideration she has given to the potential impact of the use of Depo-Provera on trends in the level of meningioma.
The Medicines and Healthcare products Regulatory Agency (MHRA) is an executive agency of the Department of Health and Social Care and regulates medicine, medical devices and blood components for transfusion in the United Kingdom, with responsibility for ensuring medicines meet appropriate standards of safety, quality, and efficacy.
Depo-Provera is an effective injectable contraceptive which contains medroxyprogesterone acetate (MPA), a synthetic form of progesterone, and provides 12 weeks of contraception.
Meningiomas are generally non-cancerous (benign) brain tumours which affect the meninges, the thin layer of tissue surrounding the brain and spinal cord. In recent years, meningioma has rarely been associated with long-term use of high doses of some synthetic forms of progesterone, including cyproterone acetate and nomegestrol.
The MHRA has not examined the impact of Depo-Provera use on trends in meningioma diagnoses. However, the product information for Depo-Provera was updated after a study published in 2024 showed an excess risk of meningioma with high dose MPA. The marketing authorisation holder subsequently wrote to UK healthcare professionals with updated advice on managing this risk. Additional studies have since confirmed the association, and the MHRA is conducting research using UK Clinical Practice Research Datalink data to compare the risks of meningioma, fracture and osteoporosis associated with injectable depot MPA and other contraceptives.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve brain tumour research.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help improve brain tumour research.
To ask the Secretary of State for Health and Social Care, what estimate she has made of the annual NHS expenditure on the treatment and management of low-grade glioma patients in England.
To ask the Secretary of State for Health and Social Care, what estimate she has made of the annual NHS expenditure on the treatment and management of low-grade glioma patients in England.
I refer the Hon Member to the answer provided to the Hon Member for Chingford and Woodford Green on 26 May 2026 in response to Question 1100.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the availability of specialist treatment services for patients diagnosed with low-grade glioma across England.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the availability of specialist treatment services for patients diagnosed with low-grade glioma across England.
I refer the Hon Member to the answer provided to the Hon Member for Chingford and Woodford Green on 26 May 2026 in response to Question 1100.
To ask the Secretary of State for Health and Social Care, whether she will make representations to NuvationBio to encourage access to the SIGMA Phase 3 trial of Safusideniv for eligible patients at UK hospitals.
To ask the Secretary of State for Health and Social Care, whether she will make representations to NuvationBio to encourage access to the SIGMA Phase 3 trial of Safusideniv for eligible patients at UK hospitals.
To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with Nuvation Bio about bringing clinical trials of Safusidenib to the UK for patients with IDH1-mutant Astrocytomas who have previously received radiotherapy and chemotherapy.
To ask the Secretary of State for Health and Social Care, whether her Department has had discussions with Nuvation Bio about bringing clinical trials of Safusidenib to the UK for patients with IDH1-mutant Astrocytomas who have previously received radiotherapy and chemotherapy.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve diagnosis (a) accuracy and (b) times for brain tumours.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve diagnosis (a) accuracy and (b) times for brain tumours.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to increase awareness of the symptoms of gliomas.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to increase awareness of the symptoms of gliomas.
To ask the Secretary of State for Health and Social Care, what recent assessment her department has made of the effectiveness of treatment offered in the UK for gliomas.
To ask the Secretary of State for Health and Social Care, what recent assessment her department has made of the effectiveness of treatment offered in the UK for gliomas.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to ensure people can access effective treatment for brain tumours in NHS hospitals.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to ensure people can access effective treatment for brain tumours in NHS hospitals.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve (a) mental and (b) emotional support for people with brain tumours.
To ask the Secretary of State for Health and Social Care, what steps she is taking to improve (a) mental and (b) emotional support for people with brain tumours.
To ask the Secretary of State for Health and Social Care, what funding her Department has allocated to research into low-grade glioma in each of the last five years.
To ask the Secretary of State for Health and Social Care, what funding her Department has allocated to research into low-grade glioma in each of the last five years.
To ask the Secretary of State for Health and Social Care, whether her Department plans to increase investment in research relating to low-grade glioma over the next spending period.
To ask the Secretary of State for Health and Social Care, whether her Department plans to increase investment in research relating to low-grade glioma over the next spending period.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that funding decisions for brain tumour research reflect the prevalence and clinical impact of low-grade glioma.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that funding decisions for brain tumour research reflect the prevalence and clinical impact of low-grade glioma.
Like many colleagues who have spoken, I pay tribute to Sir David Amess.
Today, I make a speech that I never thought I would have to make, to pay tribute to a good friend, Councillor Shanika Mahendran, who passed away on 1 July at the age of just 28. I met...
Like many colleagues who have spoken, I pay tribute to Sir David Amess.
Today, I make a speech that I never thought I would have to make, to pay tribute to a good friend, Councillor Shanika Mahendran, who passed away on 1 July at the age of just 28. I met...
To ask the Secretary of State for Health and Social Care, What funding will he make available for the National Institute for Health and Care Research Brain Tumour Research Consortium in the next financial year.
To ask the Secretary of State for Health and Social Care, What funding will he make available for the National Institute for Health and Care Research Brain Tumour Research Consortium in the next financial year.
We are committed to furthering our investment in brain cancer research and have already taken steps to stimulate scientific progress and build scientific capacity to do research on brain cancer.
In January 2026, the National Institute for Health and Care Research (NIHR) announced increased investment of over £25 million in the NIHR Brain Tumour Research Consortium. This includes an initial investment of £13.7 million announced in December 2025, and a further investment of a minimum of £11.7 million through funding of work packages announced in January 2026.
Future payments will be issued over the period of the award contracts which range from five to 10 years, as per the schedule of payments agreed between the NIHR and the Consortium.
Information on all awards will be made publicly available in due course. The NIHR is working to ensure that new investments can get up and running as soon as possible.
In addition, the NIHR continues to strongly encourage brain cancer research applications through its regular funding opportunities.